Clinical Significance of Fusobacterium nucleatum and Microsatellite Instability in Evaluating Colorectal Cancer Prognosis

References

• Siegel RL, Miller KD, Sauer AG, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70:34.
   Web of Science ®Google Scholar
• Krajewski KM. Therapy response imaging in genitourinary malignancies. In: Therapy Response Imaging in Oncology; 2020.
   Google Scholar
• Yan X, Liu L, Li H, Qin H, Sun Z. Clinical significance of Fusobacterium nucleatum, epithelial–mesenchymal transition, and cancer stem cell markers in stage III/IV colorectal cancer patients. Onco Targets Ther. 2017;10:5031. doi:10.2147/OTT.S145949
   PubMed Web of Science ®Google Scholar
• Lichtenstern CR, Ngu RK, Shalapour S, Karin M. Immunotherapy, inflammation and colorectal cancer. Cells. 2020;9(3):618. doi:10.3390/cells9030618
   PubMed Web of Science ®Google Scholar
• Raptis S. Genetic instability in human tumors. Cancer. 2006;96(Chapter13):303.
   Google Scholar
• Thibodeau S, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993;260(5109):816–819. doi:10.1126/science.8484122
   PubMed Web of Science ®Google Scholar
• Ghanipour L, Jirström K, Sundström M, et al.Associations of defect mismatch repair genes with prognosis and heredity in sporadic colorectal cancer. Eur J Surg Oncol. 2017;3(2):311–321.
   Web of Science ®Google Scholar
• Reinacher-Schick A, Arnold D, Trarbach T, Ridwelski K, Schmoll HJ. Adjuvante Therapie des Kolonkarzinoms [Adjuvant therapy in colon cancer]. Onkologie. 2010;33(4):2–7. German. doi:10.1159/000308436
   PubMedGoogle Scholar
• Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–375. doi:10.1038/s41575-019-0126-x
   PubMed Web of Science ®Google Scholar
• Wang S-M, Jiang B, Deng Y-P, Huang S-L, Fang M-Z, Wang Y. Clinical significance of MLH1/MSH2 for stage II/III sporadic colorectal cancer. World J Gastrointest Oncol. 2019;11(11):1065–1080. doi:10.4251/wjgo.v11.i11.1065
   PubMed Web of Science ®Google Scholar
• Akin H, T?Zün N. Diet, microbiota, and colorectal cancer. J Clin Gastroenterol. 2014;48(Supplement 1):S67. doi:10.1097/MCG.0000000000000252
   PubMed Web of Science ®Google Scholar
• Marinelli L, Tenore GC, Novellino E. Probiotic species in the modulation of the anticancer immune response. Paper presented at: Seminars in cancer biology; 2017.
   Google Scholar
• Yoon H, Kim N, Park JH; et al. Comparisons of gut microbiota among healthy control, patients with conventional adenoma, sessile serrated adenoma, and colorectal cancer. J Cancer Prev. 2017;22(2):108–114. doi:10.15430/JCP.2017.22.2.108
   PubMed Web of Science ®Google Scholar
• Irrazábal T, Belcheva A, Girardin S, Martin A, Philpott D. The multifaceted role of the intestinal microbiota in colon cancer. Mol Cell. 2014;54(2):309–320. doi:10.1016/j.molcel.2014.03.039
   PubMed Web of Science ®Google Scholar
• Ito M, Kanno S, Nosho K, et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer. 2015;137(6):1258–1268. doi:10.1002/ijc.29488
   PubMed Web of Science ®Google Scholar
• Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016;65(12):1973–1980. doi:10.1136/gutjnl-2015-310101
   PubMed Web of Science ®Google Scholar
• Liu K, Yang X, Zeng M, et al. The role of fecal Fusobacterium nucleatum and pks+ Escherichia coli as early diagnostic markers of colorectal cancer. Dis Markers. 2021;2021:31.
   Web of Science ®Google Scholar
• Lee D-W, Han S-W, Kang J-K, et al. Association between Fusobacterium nucleatum, pathway mutation, and patient prognosis in colorectal cancer. Ann Surg Oncol. 2018;25(11):3389–3395. doi:10.1245/s10434-018-6681-5
   PubMed Web of Science ®Google Scholar
• Tahara T, Yamamoto E, Suzuki H, et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res. 2014;74(5):1311–1318. doi:10.1158/0008-5472.CAN-13-1865
   PubMed Web of Science ®Google Scholar
• Park HE, Kim JH, Cho NY, et al. Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma. Virchows Archiv. 2017;471(3):1–8.
   Web of Science ®Google Scholar
• Ogino S, Nosho K, Irahara N, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 2009;15(20):6412–6420. doi:10.1158/1078-0432.CCR-09-1438
   PubMed Web of Science ®Google Scholar
• Mima K, Sukawa Y, Nishihara R, Zhi RQ, Ogino S. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA oncol. 2015;1:5. doi:10.1001/jamaoncol.2015.1377
   Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409. doi:10.1126/science.aan6733
   PubMed Web of Science ®Google Scholar
• Baylin SB, Jones PA. A decade of exploring the cancer epigenome—biological and translational implications. Nat Rev Cancer. 2011;11(10):726–734. doi:10.1038/nrc3130
   PubMed Web of Science ®Google Scholar
• Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: part I. The utility of immunohistochemistry. J Mol Diag. 2008;10(4):293–300. doi:10.2353/jmoldx.2008.080031
   PubMed Web of Science ®Google Scholar
• Jiao S, Peters U, Berndt S, et al. Estimating the heritability of colorectal cancer. Hum Mol Genet. 2014.
   Web of Science ®Google Scholar
• Graff RE, Moller S, Passarelli MN, et al. Familial risk and heritability of colorectal cancer in the nordic twin study of cancer. Clin Gastroenterol Hepatol. 2017;15(8):1256–1264. doi:10.1016/j.cgh.2016.12.041
   PubMed Web of Science ®Google Scholar
• Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer — analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78–85. doi:10.1056/NEJM200007133430201
   PubMed Web of Science ®Google Scholar
• Derosa L, Routy B, Kroemer G, Zitvogel L. The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1. OncoImmunology. 2018;7(6):e1434468. doi:10.1080/2162402X.2018.1434468
   PubMed Web of Science ®Google Scholar
• Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14(2):195–206. doi:10.1016/j.chom.2013.07.012
   PubMed Web of Science ®Google Scholar
• Kostic A, Chun E, Robertson L. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14(2):207–215. doi:10.1016/j.chom.2013.07.007
   PubMed Web of Science ®Google Scholar
• Yu TC, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170(3):548. doi:10.1016/j.cell.2017.07.008
   PubMed Web of Science ®Google Scholar
• Oh HJ, Kim JH, Bae JM, Kim HJ, Cho N-Y, Kang GH. Prognostic impact of Fusobacterium nucleatum depends on combined tumor location and microsatellite instability status in stage II/III colorectal cancers treated with adjuvant chemotherapy. J Pathol Transl Med. 2019;53(1):40. doi:10.4132/jptm.2018.11.29
   PubMed Web of Science ®Google Scholar
• Guo S, Li L, Xu B, et al. A simple and novel fecal biomarker for colorectal cancer: ratio of Fusobacterium nucleatum to probiotics populations, based on their antagonistic effect. Clin Chem. 2018;64(9):1327–1337. doi:10.1373/clinchem.2018.289728
   PubMed Web of Science ®Google Scholar
• Eisele Y, Mallea PM, Gigic B, Stephens WZ, Ose J. Fusobacterium nucleatum and clinicopathologic features of colorectal cancer: results from the ColoCare study. Clin Colorectal Cancer. 2021;20(3):e165–e172. doi:10.1016/j.clcc.2021.02.007
   PubMed Web of Science ®Google Scholar
• Falony G, Vieira-Silva S, Raes J. Richness and ecosystem development across faecal snapshots of the gut microbiota. Nat Microbiol. 2018;3(5):526–528. doi:10.1038/s41564-018-0143-5
   PubMed Web of Science ®Google Scholar
• Wang S, Liu Y, Li J, et al. Fusobacterium nucleatum acts as a pro-carcinogenic bacterium in colorectal cancer: from association to causality. Front Cell Develop Biol. 2021;9:34.
   Web of Science ®Google Scholar
• Chen Y, Yan P, Yu J, Chen T, Fu X. Invasive Fusobacterium nucleatum activates beta-catenin signaling in colorectal cancer via a TLR4/P-PAK1 cascade. Oncotarget. 2017;8(19):31802–31814. doi:10.18632/oncotarget.15992
   PubMedGoogle Scholar
• Shen W, Sun J, Yao F, Lin K, Jiao X. Microbiome in intestinal lavage fluid may be a better indicator in evaluating the risk of developing colorectal cancer compared with fecal samples. Transl Oncol. 2020;13(5):100772. doi:10.1016/j.tranon.2020.100772
   PubMed Web of Science ®Google Scholar
• Fan L, Qi Y, Qu S, Chen X, Chen S. B. adolescentis ameliorates chronic colitis by regulating Treg/Th2 response and gut microbiota remodeling. Gut Microbes. 2021;13(1):1–17. doi:10.1080/19490976.2020.1826746
   PubMed Web of Science ®Google Scholar
• Yamaoka Y, Suehiro Y, Hashimoto S, et al. Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population. J Gastroenterol. 2018;53(4):517–524. doi:10.1007/s00535-017-1382-6
   PubMed Web of Science ®Google Scholar
• Li SKH, Martin A. Mismatch repair and colon cancer: mechanisms and therapies explored. Trends Mol Med. 2016;22(4):274. doi:10.1016/j.molmed.2016.02.003
   PubMed Web of Science ®Google Scholar
• McConechy MK, Talhouk A, Li-Chang HH, et al. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecol Oncol. 2015;32:21.
   Google Scholar
• Vogelstein B, Papadopoulos N, VE Velculescu, Zhou S, Diaz Jr L, KW Kinzler. Cancer genome landscapes. Science. 2013;339(6127):1546–1558. doi:10.1126/science.1235122
   PubMed Web of Science ®Google Scholar
• Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer. 2010;46(15):2788–2798. doi:10.1016/j.ejca.2010.05.009
   PubMed Web of Science ®Google Scholar
• Gkekas I, Novotny J, Pecen L, Strigård K, Gunnarsson U. Microsatellite instability as a prognostic factor in stage II colon cancer patients, a meta-analysis of published literature. Anticancer Res. 2017;37(12):6563. doi:10.21873/anticanres.12113
   PubMed Web of Science ®Google Scholar
• Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline summary from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. J Oncol Pract. 2017;13(5):333–337. doi:10.1200/JOP.2017.022152
   PubMed Web of Science ®Google Scholar
• Xie QQ, Chang-Ping WU, Jiang JT. Diagnostic value of s CTLA-4 combined with CEA and CA19-9 for colorectal carcinoma. Chin J Clin Lab Sci. 2015;2015:23.
   Google Scholar